According to reports, the US Food and Drug Administration (FDA) underestimated the number of pre-market tobacco product applications (PMTAs) related to synthetic nicotine (NTN) that it has reviewed to avoid criticism from tobacco control organizations seeking to ban all electronic cigarette products. Vaping360 cites Amanda Wheeler, the president of the American Vapor Manufacturers Association (AVM).
Translation: Amanda Wheeler (source: AVM)
On September 8th, the FDA announced that it has accepted over 350 PMTA applications for NTN products, totaling nearly one million submissions. Wheeler asserts that AVM member companies alone have received over 4,700 accepted PMTA notifications.
Wheeler stated in a press release, "The FDA and its Center for Tobacco Products are once again misleading the public and emphasizing key data and methods in their approval process for electronic cigarette products." "The data in today's press release regarding the synthetic nicotine application is clearly inconsistent with the letter sent to our own members by the FDA, which indicated a much greater number of successfully submitted applications than what the FDA is now claiming.
AVM has also stated that the FDA changed the required PMTA form close to the submission deadline, resulting in disqualification of applications that had already been submitted. According to Wheeler, the application form was suddenly altered without any public notice and "clearly intended to disqualify a large number of already submitted applications.
In March, US President Joe Biden signed legislation authorizing the FDA to regulate synthetic nicotine products. Manufacturers must submit a PMTA by May 14th and have an additional two months to continue selling products with pending PMTAs. When the grace period ends on July 13th, all synthetic nicotine-based products will be subject to FDA enforcement.
Statement:
This article is based on compilation of third-party information and is intended solely for industry exchange and learning purposes.
This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The translation of this article is only for industry communication and research purposes.
Due to limitations in the level of translation, the translated article may not fully express the same meaning as the original. Please refer to the original article for accuracy.
2FIRSTS is completely aligned with the Chinese government in regards to any domestic, Hong Kong, Macau, Taiwan, or foreign issues and positions.
The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
